News from Bayer
September 08, 2022
Not intended for U.S. and UK Media
Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients
September 01, 2022
Kimberly Mathisen appointed to the Supervisory Board of Bayer AG
August 28, 2022
Not intended for U.S. and UK Media
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
Explore All Stories
Please enter a term to search